Products Categories
CAS No.: | 10124-50-2 |
---|---|
Name: | POTASSIUM ARSENITE |
Molecular Structure: | |
Formula: | AsH3 O3 . x K |
Molecular Weight: | 399.65 |
Synonyms: | Arseniousacid (H3AsO3), potassium salt (8CI); Arsenous acid, potassium salt; NSC 3060;Potassium arsenite; Potassium arsonate |
Density: | g/cm3 |
Melting Point: | 300℃ (decomposes) |
Boiling Point: | °Cat760mmHg |
Flash Point: | °C |
Solubility: | miscible |
Hazard Symbols: | Toxic by ingestion and inhalation, strong irritant. |
Safety: | Confirmed human carcinogen producing skin and liver tumors. Poison by ingestion, skin contact, subcutaneous, and intravenous routes. Human mutation data reported. Human systemic effects: dermatitis, liver changes. When heated to decomposition it emits toxic fumes of As and K2O. Used in veterinary medicine and for chronic dermatitis in humans. See also ARSENIC COMPOUNDS. |
PSA: | 69.18000 |
LogP: | -0.73720 |
MF: AsKO2
MW: 146.02
EINECS: 233-337-9
Appearance: White hygroscopic powder
Air & Water Reactions: Soluble in water. Decomposes slowly in air.
Synonyms: Potassium arsonate ; potassium arsonate ; Kaliumarsenit ; Arsenous acid tripotassium salt ; Arsonic acid/potassium,(1:x) salt
Following is the molecular structure of Potassium arsonate (10124-50-2):
Potassium arsenite (10124-50-2) is the compound which forms the basis of Fowler's solution and is used as a specific rodenticide.
Reactivity Profile: Salts, basic, such as Potassium arsonate (10124-50-2), are generally soluble in water. The resulting solutions contain moderate concentrations of hydroxide ions and have pH's greater than 7.0. They react as bases to neutralize acids. These neutralizations generate heat, but less or far less than is generated by neutralization of the bases in reactivity group 10 (Bases) and the neutralization of amines. They usually do not react as either oxidizing agents or reducing agents but such behavior is not impossible. Fire may produce irritating or poisonous gases. Unstable. Avoid aeration.
1. | cyt-hmn:leu 1 µmol/L/48H | CNREA8 Cancer Research. 25 (1965),980. | ||
2. | orl-man TDLo:214 mg/kg/15Y-C:CAR,LIV | GASTAB Gastroenterology. 68 (1975),1582. | ||
3. | orl-man TD:7560 mg/kg/26W-C:CAR,SKN | ANSUA5 Annals of Surgery. 99 (1934),348. | ||
4. | orl-man TD:441 mg/kg/3W-C:CAR,SKN | ANSUA5 Annals of Surgery. 99 (1934),348. | ||
5. | orl-chd TD:390 mg/kg/3Y-C:CAR,SKN | AIMEAS Annals of Internal Medicine. 61 (1964),296. | ||
6. | orl-hmn TDLo:74 mg/kg:LIV,SKN | LANCAO Lancet. 1 (1953),269. | ||
7. | orl-rat LD50:14 mg/kg | AFDOAQ Association of Food and Drug Officials of the United States, Quarterly Bulletin. 15 (1951),122. | ||
8. | skn-rat LD50:150 mg/kg | PHJOAV Pharmaceutical Journal. 185 (1960),361. | ||
9. | scu-mus LDLo:16 mg/kg | HBAMAK Abdernaldens Handbuch der Biologischen Arbeitsmethoden. 4 (1935),1307. | ||
10. | orl-dog LDLo:3 mg/kg | HBAMAK Abdernaldens Handbuch der Biologischen Arbeitsmethoden. 4 (1935),1307. | ||
11. | &nbs |
NTP 10th Report on Carcinogens. IARC Cancer Review: Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 23 ,1980,p. 39.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 23 ,1980,p. 39.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 2 ,1973,p. 48.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) . Arsenic and its compounds are on the Community Right-To-Know List. EPA Extremely Hazardous Substances List.
Confirmed human carcinogen producing skin and liver tumors. Poison by ingestion, skin contact, subcutaneous, and intravenous routes. Human mutation data reported. Human systemic effects: dermatitis, liver changes. When heated to decomposition it emits toxic fumes of As and K2O. Used in veterinary medicine and for chronic dermatitis in humans.
OSHA PEL: TWA 0.01 mg(As)/m3; Cancer Hazard
ACGIH TLV: BEI: 35 µ (As)/L inorganic arsenic and methylated metabolites in urine
NIOSH REL: CL (Inorganic Arsenic) 0.002 mg(As)/m3/15M
DOT Classification: 6.1; Label: Poison